Detection and Whole-Genome Analysis of a High-Risk Clone of ST340/CG258 Producing CTX-M-15 in a Companion Animal.
Clicks: 319
ID: 70144
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
79.7
/100
317 views
256 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The emergence and dissemination of high-risk clones of producing extended-spectrum β-lactamases (ESBLs) in animal infections is a critical issue. We report the detection and genomic features of a multidrug-resistant (MDR) ESBL (CTX-M-15)-producing infecting a domestic cat. Whole-genome sequencing analysis identified the international ST340 (clonal group CG258), and genes and mutations conferring resistance to β-lactams, aminoglycosides, macrolides, phenicols, fosfomycin, sulfonamides, tetracycline, trimethoprim, and fluoroquinolones. In addition, the presence of genes encoding resistance to disinfectant and heavy metals hazardous to humans was also confirmed. The MDR profile exhibited by the strain contributed to treatment failure and death of the companion animal. Therefore, active surveillance of critical priority lineages of should not only focus on human infections but also on veterinary infections.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (120 words).
Try re-searching for a better abstract.
| Reference Key |
valenciabacca2019detectionmicrobial
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Valencia-Bacca, Juan;Silva, Meire M;Cerdeira, Louise;Esposito, Fernanda;Cardoso, Brenda;Muñoz, Maria E;Jiménez-Villegas, Tatiana;Cardenas-Arias, Adriana;Pessoa, Danielle A N;Lincopan, Nilton; |
| Journal | microbial drug resistance (larchmont, ny) |
| Year | 2019 |
| DOI |
10.1089/mdr.2019.0190
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.